Apogee Therapeutics to Participate in Upcoming March Conferences

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026.

GlobeNewsWire • 13 hours ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $122.20 million, including changes from both trading and price movements.

The Motley Fool • Feb 22, 2026

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

Affinity Asset Advisors bought 61,500 shares of Apogee Therapeutics in the fourth quarter; the estimated transaction value was $3.87 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $46.59 million, reflecting both trade and stock price movement.

The Motley Fool • Feb 14, 2026

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

GlobeNewsWire • Feb 5, 2026

Apogee Therapeutics: 2026 Inflection Point In Immunology

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash position provides operational runway into 2028, supporting pivotal Phase II/III trials without near-term dilution risk. Zumilokibart's extended half-life and clean safety profile position APGE to challenge Dupixent, with physician surveys indicating strong preference for reduced dosing frequency.

Seeking Alpha • Jan 21, 2026

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally

The chief medical officer at Apogee Therapeutics sold 18,700 shares of the biotech for about $1.46 million. This sale represented 8.09% of Dambkowski's direct holdings, reducing his direct stake, as reported, from 231,223 to 212,523 shares.

The Motley Fool • Jan 11, 2026

Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally

10,900 shares directly sold for a total transaction value of $817,500 on Dec. 4, 2025. The transaction represented 3.87% of CMO Carl Dambkowski's direct holdings, reducing direct ownership from 282,008 to 271,108 shares.

The Motley Fool • Jan 7, 2026

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Seeking Alpha • Jan 6, 2026

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued development in asthma testing every 3- or 6-month dosing

GlobeNewsWire • Jan 6, 2026

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

GlobeNewsWire • Jan 5, 2026